Now Enrolling in Clinical Trials

Ureters

Prostate

Ureters

Bladder

Sponsor’s & CRO’S

Get in touch with us today to discuss your current or future clinical trial.

Our recruitment is driven by an established patient database, active physician network, and a dedicated team committed to advancing medicine through clinical research, reducing timelines and improving study performance.

The Advantage of Partnering With Us

Efficient Feasibility & Startup

Our team delivers fast and reliable feasibility assessments, backed by actual database insights. Regulatory packets and site activation are handled efficiently to accelerate study startup.

Patient Identification & Enrollment

We leverage our established patient database in urology and radiation oncology to identify and pre-screen qualified candidates. Our recruitment strategy ensures consistent enrollment and low screen failure rates.

Execution & Data Delivery

Our experienced investigators and coordinators ensure protocol adherence  and high-quality data. We focus on clean execution, timely reporting, and sponsor-ready performance.

Efficient Study Start-Up

We deliver efficient study start-up, strong patient enrollment, and high-quality, compliant data—supported by proactive communication and a dedicated research team.

Experienced Clinical Team

Led by skilled investigators with expertise in urology and oncology clinical trials.

High-Quality Data & Compliance

Commitment to data integrity, GCP compliance, and accurate, reliable study execution.

More About Southeast Florida Urology

Member of the Topline MD Alliance

Southeast Florida Urology provides advanced, minimally invasive office-based laser procedures for conditions affecting the urethra, bladder, and prostate. SEF also offer access to state of the art treatments for kidney stone disease and urologic cancers, delivering comprehensive and personalized care to our patients.

Our Mission

Improving patient outcomes by connecting medical excellence with innovative research.

Patient Care

Collaborating with patients and physicians to improve outcomes.

Research

Advancing science to drive the future of precision medicine.

Clinical Trials

Conducting phase 1-4 clinical trials across urology and urological uncology.

Dr. Robert H. Sherman, MD. (FACS)

Principal Investigator

Has been a Urologist and Urological surgeon in South Florida since 1989. He is board-certified and is on the medical staff of Memorial Hospitals West and Miramar as well as Broward Specialty Surgical Center where he performs the majority or his outpatient surgeries. He grew up in Philadelphia, Pennsylvania. He received his medical degree at Temple University and his Urological training at University of California. He practices general Urology with emphasis on kidney stones, voiding abnormalities, erectile dysfunction, low testosterone, infertility, and Urological malignancies including kidney, prostate and bladder cancers.
Dr. Sherman speaks English, Spanish and French.

Arthur J. Iglesias, MD.

Sub-Investigator

Dr Arthur J. iglesias is a radiation oncologist in El Portal, Florida and is affiliated with multiple hospitals in the area, including HCA Florida Woodmont Hospital and North Shore Medical Center-Miami. He received his medical degree from American University of the Caribbean School of Medicine and has been in practice for more than 20 years. He treat cancer using various forms of radiation to detect and kill malignant cells. Radiation therapy is often combined with other modes of treatment, especially surgery and chemotherapy.

Victor M. Soto, RT. (ARRT)

Clinical Trials Project Director & Lead Coordinator

Victor M. Soto, RT (ARRT), is an ARRT-certified Radiologic Technologist since 2018 and a graduate of Florida National University. He serves as the Site Director and Lead Coordinator at Promed Research Center, where he oversees clinical trial operations, regulatory compliance, patient recruitment, and study coordination. With a strong commitment to advancing medical research and improving patient outcomes, Victor is currently pursuing his Certified Clinical Research Professional (CCRP) certification.

Ericka Sutherland, CMA.

Clinical Research Coordinator

Ericka Sutherland is a Certified Medical Assistant, Clinical Research Coordinator and phlebotomy specialist, trained at Keiser College. With nearly two decades of experience in urology care since 2006, she supports patient exams, procedures, and laboratory specimen collection. At Promed Research Center, she plays a key role in clinical operations, ensuring accurate sample handling and patient care.

Shavon Garcia

Data Entry Specialist

Shavon Garcia is an experienced Data Entry Specialist with more than 10 years of experience working in the urology medical field at our practice. She plays an important role in supporting daily clinical operations by maintaining accurate patient information, assisting with medical documentation, and helping ensure smooth communication within the care team.

Michelle White

Patient Identification & Enrollment Specialist

Michelle White plays an important role in patient identification and enrollment for our clinical research studies. She specializes in pre-screening potential candidates based on study inclusion and exclusion criteria and supports communication with patients throughout their study visits to help ensure a smooth clinical trial experience.

Leslie G. Shawn, MD.

Sub-Investigator

Dr. Leslie Shawn is a board-certified family medicine physician with more than 50 years of medical experience. He earned his medical degree in 1973 from the University of North Texas Health Science Center at Fort Worth and completed his internship at Botsford Hospital in 1974.
He is affiliated with Memorial Hospital Miramar and Memorial Hospital West and is dedicated to providing comprehensive, patient-focused care to the community in Pembroke Pines, Florida.

Lilianny Montano, BSN.

Clinical Research Nurse

Lilianny Montano is a Registered Nurse (BSN) with clinical experience in medical-surgical care, cardiology, psychiatry, and patient monitoring. She earned her Bachelor of Science in nursing (BSN) from Miami Dade College medical campus.
She is certified in BLS/ACLS, GCP, OSHA, HIPAA, IATA, and ECG Rhythm Recognition. Lilianny has hands-on experience with patient assessments, medication administration, IV insertion, blood collection, ECG monitoring, and Epic charting through clinical training at Jackson Memorial Hospital, University of Miami Hospital, Aventura Hospital, and Jackson North. Bilingual, English and Spanish, she is dedicated to providing patient-centered care.

Provepharm Inc

PVP-22IC04

Provepharm, a pharmaceutical company specializing in high-quality, effective, ready-to-use medical dyes designed to optimize visualization and detection in clinical practice.

This is a randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Indigotindisulfonate Sodium Injection, USP 0.8% when used as an aid in the determination of ureteral patency.

More about this clinical Study

    This clinical research study is evaluating two dose levels (2.5 mL and 5.0 mL) of Indigotindisulfonate Sodium Injection, USP 0.8% to determine its safety and effectiveness as an aid in assessing ureteral patency during cystoscopy.

    Researchers aim to determine how well the study medication helps physicians visualize urine flow from the ureters following surgery, supporting accurate evaluation of urinary tract function.

    Adults ages 18–85 who are scheduled for a surgical procedure requiring cystoscopic assessment of ureteral patency may be eligible to participate. Participants must provide written informed consent and meet all study eligibility requirements.

     

    Provepharm Inc

    PVP-22IC05

    Provepharm, a pharmaceutical company specializing in high-quality, effective, ready-to-use medical dyes designed to optimize visualization and detection in clinical practice.

    To assess the efficacy of Bludigo™️ 2.5mL and 5.0mL in patients with normal renal function (eGFR ≥ 90 mL/min) and in patients with mild, moderate and severe renal impairment (eGFR 60-89 mL/min, 30 – 59 mL/min, and 15 – 29 mL/min, respectively) utilizing a validated conspicuity scale designed to provide an objective tool applicable to the visualization of the urine jet stream when determining ureter patency.

    Study Overview

    The study will assess how well Bludigo™️ helps visualize the urine jet stream during cystoscopy to confirm ureter patency after surgery. Participants may have normal kidney function or mild, moderate, or severe renal impairment based on eGFR levels.

    Adults ages 18–85 who are scheduled for a procedure requiring cystoscopic evaluation of ureter patency and meet kidney function requirements may be eligible. Participants must provide written informed consent and meet all study health and safety criteria.

     

    Wren Laboratories

    WL-PROSTest-1

    Wren Laboratories Transforming cancer diagnostics and precision medicine through novel liquid biopsy mRNA technology

    A single-arm, multicenter prospective study to evaluate the diagnostic performance of PROSTest in men with PSA ≥ 3 ng/mL using biopsy as the sole ground truth.

    Study Overview

    A single-arm, multicenter, prospective clinical study designed to evaluate the diagnostic performance of PROSTest, a novel liquid biopsy mRNA test developed by Wren Laboratories. The study aims to assess the ability of PROSTest to identify clinically significant prostate cancer in men with elevated PSA levels by comparing test results with prostate biopsy findings, which serve as the study’s reference standard.

    By participating, patients contribute to the development of innovative diagnostic technologies that may help improve prostate cancer detection and support more informed clinical decision-making in the future.

     

    Surge Therapeutics

    STM-416-01

    SURGE (The Intraoperative Immunotherapy Company') seeks to change the standard of care for cancer patients by transforming how, when, and where cancer immunotherapy is deployed in order to dramatically improve survival outcomes.

    A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer

    Are You Living with Non-Muscle Invasive Bladder Cancer (NMIBC)?

    If so, you may be eligible to participate in the LAUREL Study, a clinical research trial evaluating an investigational treatment for patients with NMIBC who are undergoing surgery to remove a bladder tumor (TURBT).

    The purpose of this study is to assess the safety of the study medication and determine whether it may help reduce the risk of cancer recurrence after surgery.

    By participating, you may contribute to the advancement of future treatment options for patients living with NMIBC.